PAX5 and Down syndrome: The fact that PAX5 re-expression normalizes growth and differentiation in pre-B ALL with divergent genetic backgrounds and mutational signatures, including with Down syndrome associated ALL as tested in primary cells, suggests that even after cooperating mutations have arisen, loss of PAX5 activity continues to support the leukemic state.